Share
News
-
29 August 2008 /Side effects and trials
EU directive does not result in fewer clinical trials from independent researchers
In 2004, when the CT directive came into force, the GCP-rules became mandatory for the independent researchers and they were to meet the same requirements as their colleagues in the pharmaceutical industry - something which led many people to fear that it would result in less public research.
-
27 August 2008 /Product information
Thalidomide Pharmion (thalidomide) on the Danish market as of 25 August 2008
Thalidomide Pharmion is authorised in the EU as first line treatment of multiple myeloma, which is a relatively rare cancer of the bone marrow. Thalidomide Pharmion must be given in combination with the medicines melphalan and prednisone.
-
13 August 2008 /Side effects and trials
EMEA assesses incidents of progressive multifocal leukoencephalopathy (PML) in sclerosis patients receiving Tysabri®
The European Medicines Agency (EMEA) has received two reports of progressive multifocal leukoencephalopathy (PML) in patients with relapsing-remitting multiple sclerosis (MS).
-
11 August 2008 /Side effects and trials
Antiepileptics and increased risk of suicidal thoughts and behaviour
The European Medicines Agency (EMEA) has concluded that antiepileptics may entail a slight risk of suicidal thoughts and behaviour.
-
11 August 2008 /Product information
Warning against the product Melanotan
The Danish Medicines Agency has been made aware of the product, Melanotan, which is sold via the internet. The product is marketed as a product that increases pigmentation, providing tanned skin and protection against the harmful rays of the sun, implying that it may prevent skin cancer. However, this effect has not been documented.
